Discover cutting-edge studies on carcinogenesis, biomarkers, and targeted therapeutic approaches
Explore how DFG-out binding mode BRAF inhibitors are transforming melanoma treatment by targeting both monomeric and dimeric BRAF mutations.
Exploring how triazole-substituted N-hydroxyindol-2-carboxylates inhibit hLDH5 to disrupt cancer metabolism